Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining about their Boards, even if just for entertaining effect on conference panels and the like.
Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter. It’s a 2013 New Yorker article chronicling one woman’s journey through years of multi-symptom autoimmune/autoinflammatory disease with undiagnosed and untreated maladies. It’s a long read, but one that I could not leave unfinished as I thought about my multiple friends who followed similar paths for years, each trying to understand what caused her symptoms. Amongst my close friends are one with multiple sclerosis, one with ulcerative colitis, one with lupus and two with rheumatoid arthritis (RA). Their diseases are given these titles that imply crisp definitions, but these are heterogenous diseases with overlapping symptoms, so they are difficult to diagnose and treat. I’ll come back to what we might do to change that.
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.
“It takes twenty years to build a reputation, and five minutes to ruin it,” Warren Buffett said, and added “If you think about that, you’ll do things differently.” In biotech, a strong reputation is difficult to build, is even harder to establish quickly, and can be easily tarnished. So, what’s the landscape and what should we do about it?
This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC.
Obsidian Therapeutics has named Paul Wotton as CEO. The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.
Life science-focused venture capital firms Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners (OUP) have partnered to create Science2Startup (S2S)™, an invitation-only symposium aimed at strengthening connections between biotech investors and therapeutics researchers at the world’s top academic research institutions. S2S will take place on April 23, 2019, in Cambridge at the Broad Institute of MIT and Harvard.